Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. (Q37701838)
Jump to navigation
Jump to search
scientific article published on 30 June 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. |
scientific article published on 30 June 2016 |
Statements
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial (English)
Alberto Auricchio
Francesca Simonelli
Albert M Maguire
Kathleen A Marshall
Jean Bennett
Jennifer Wellman
Sarah McCague
Manzar Ashtari
Julie DiStefano-Pappas
Okan U Elci
Daniel C Chung
Junwei Sun
J Fraser Wright
Dominique R Cross
Puya Aravand
Laura L Cyckowski
Jeannette L Bennicelli
Jason Ruggiero